Neuren Pharmaceuticals Ltd (NEU) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.397x

Based on the latest financial reports, Neuren Pharmaceuticals Ltd (NEU) has a cash flow conversion efficiency ratio of 0.397x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$128.31 Million ≈ $90.78 Million USD) by net assets (AU$323.27 Million ≈ $228.74 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NEU net asset quality index to measure how much of total assets are equity-financed.

Neuren Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2002–2024)

This chart illustrates how Neuren Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Neuren Pharmaceuticals Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.

Neuren Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Neuren Pharmaceuticals Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Klabin S.A
SA:KLBN3
0.058x
Gas Malaysia Bhd
KLSE:5209
0.049x
Lao Feng Xiang Co Ltd A
SHG:600612
-0.144x
FLEX LNG Ltd
NYSE:FLNG
0.040x
Fortress Income Fund Ltd
JSE:FFB
0.032x
China Cinda Asset Management Co., Ltd.
F:0CI
N/A
Robertet SA
PA:RBT
0.130x
Corporate Travel Management Ltd
AU:CTD
0.010x

Annual Cash Flow Conversion Efficiency for Neuren Pharmaceuticals Ltd (2002–2024)

The table below shows the annual cash flow conversion efficiency of Neuren Pharmaceuticals Ltd from 2002 to 2024. For the full company profile with market capitalisation and key ratios, see NEU market cap.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 AU$363.90 Million
≈ $257.49 Million
AU$-11.27 Million
≈ $-7.97 Million
-0.031x -103.44%
2023-12-31 AU$205.21 Million
≈ $145.20 Million
AU$184.93 Million
≈ $130.85 Million
0.901x +941.36%
2022-12-31 AU$41.59 Million
≈ $29.43 Million
AU$3.60 Million
≈ $2.55 Million
0.087x +134.07%
2021-12-31 AU$39.25 Million
≈ $27.77 Million
AU$-9.97 Million
≈ $-7.05 Million
-0.254x +23.91%
2020-12-31 AU$24.20 Million
≈ $17.12 Million
AU$-8.08 Million
≈ $-5.72 Million
-0.334x +60.56%
2019-12-31 AU$13.85 Million
≈ $9.80 Million
AU$-11.72 Million
≈ $-8.29 Million
-0.846x -425.81%
2018-12-31 AU$24.67 Million
≈ $17.45 Million
AU$6.41 Million
≈ $4.53 Million
0.260x +176.04%
2017-12-31 AU$16.36 Million
≈ $11.58 Million
AU$-5.59 Million
≈ $-3.96 Million
-0.342x +88.46%
2016-12-31 AU$4.18 Million
≈ $2.96 Million
AU$-12.38 Million
≈ $-8.76 Million
-2.959x -234.75%
2015-12-31 AU$14.40 Million
≈ $10.19 Million
AU$-12.73 Million
≈ $-9.01 Million
-0.884x -163.10%
2014-12-31 AU$19.08 Million
≈ $13.50 Million
AU$-6.41 Million
≈ $-4.54 Million
-0.336x -6.14%
2013-12-31 AU$24.36 Million
≈ $17.23 Million
AU$-7.71 Million
≈ $-5.45 Million
-0.317x +31.96%
2012-12-31 AU$6.34 Million
≈ $4.49 Million
AU$-2.95 Million
≈ $-2.09 Million
-0.465x -40.59%
2011-12-31 AU$9.45 Million
≈ $6.69 Million
AU$-3.13 Million
≈ $-2.21 Million
-0.331x +59.31%
2010-12-31 AU$3.53 Million
≈ $2.50 Million
AU$-2.87 Million
≈ $-2.03 Million
-0.813x -364.34%
2009-12-31 AU$7.35 Million
≈ $5.20 Million
AU$-1.29 Million
≈ $-910.66K
-0.175x +89.20%
2008-12-31 AU$5.57 Million
≈ $3.94 Million
AU$-9.04 Million
≈ $-6.40 Million
-1.622x -6.50%
2007-12-31 AU$7.55 Million
≈ $5.34 Million
AU$-11.50 Million
≈ $-8.14 Million
-1.523x -169.10%
2006-12-31 AU$16.15 Million
≈ $11.42 Million
AU$-9.14 Million
≈ $-6.47 Million
-0.566x -116.92%
2005-12-31 AU$32.16 Million
≈ $22.75 Million
AU$-8.39 Million
≈ $-5.94 Million
-0.261x +37.81%
2004-12-31 AU$8.77 Million
≈ $6.20 Million
AU$-3.68 Million
≈ $-2.60 Million
-0.420x -232.00%
2003-12-31 AU$-14.72 Million
≈ $-10.41 Million
AU$-4.68 Million
≈ $-3.31 Million
0.318x +111.17%
2002-12-31 AU$1.82 Million
≈ $1.29 Million
AU$-5.19 Million
≈ $-3.67 Million
-2.846x --

About Neuren Pharmaceuticals Ltd

AU:NEU Australia Biotechnology
Market Cap
$1.67 Billion
AU$2.35 Billion AUD
Market Cap Rank
#6742 Global
#157 in Australia
Share Price
AU$18.59
Change (1 day)
+3.28%
52-Week Range
AU$11.28 - AU$21.98
All Time High
AU$25.11
About

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 cl… Read more